TP53 and acute myeloid leukemia: In a Phase 2 trial, nivolumab, an anti-PD-1 antibody, was combined with idarubicin or cytarabine in newly diagnosed high-risk MDS/AML patients, including those with TP53 mutations (NCT02464657) [199].